Procept's receptor advances attract partners
Procept's receptor advances attract partners Procept Inc. 's ability to isolate specific cellular targets has led to its third corporate partnership, with Sandoz Pharma Ltd.
Sandoz is investing up to $29 million in the privately held immunology-based company to develop small-molecule drugs to treat autoimmune diseases and organ transplantation rejection by isolating CD4 and CD2 receptors.
According to Stanley Erck, Procept president and CEO, the specificity of the company's technology has attracted its partners. "You can have